KIRKLAND, Wash.--Bioinformatics company Rosetta Inpharmatics here and genomics drug discovery company Acacia Biosciences announced this month that they have signed a merger agreement whereby Rosetta will acquire Acacia in a stock-for-stock transaction.
John Friend, Rosetta's president and chief scientific officer, said, "The merger significantly increases the scope, value, and proprietary position of Rosetta to pharmaceutical, biotechnology, and agrichemical collaborators." He added, "The exceptional fit between Acacia and Rosetta's technology platforms and scientific resources will greatly accelerate the commercialization of our genome-wide assay systems for cellular analysis, including target identification and gene expression profiling."
Friend contended that "the informatics and biotechnology fields will need to find better ways to offer their customers integrated, comprehensive solutions, rather than fragmented or partial solutions." He continued, "Any emerging company that hopes to become a leader in this field will need to become the dominant player in their area of drug discovery."
Rosetta said it will integrate Acacia's Genome Reporter Matrix and other technologies into its own drug discovery platform, which simultaneously monitors in vivo activity of compounds against all protein targets within cells, using an integrated system of informatics tools, biological platforms, and datasets. The combination of the two genome-wide analysis tools will provide a more comprehensive understanding of compounds before conducting expensive human clinical trials, reducing the risk, cost, and development time of new drugs, the company claimed.